Résumé
We report the coverage, safety, and logistics of a school-based typhoid fever immunization campaign that took place in Hue City, central Vietnam; a typhoid fever endemic area. A cluster-randomized evaluation-blinded controlled trial was designed where 68 schools (cluster) were randomly allocated the single dose Vi polysaccharide vaccine (Typherix) or the active control hepatitis A vaccine (Havrix). A safety surveillance system was implemented. A total of 32,267 children were immunized with a coverage of 57.5%. Strong predictors for vaccination were attending primary schools, peri-urban location of the school, and low family income. Human resources were mainly schoolteachers and the campaign was completed in about 1 month. Most adverse events reported were mild. Safe injection and safe sharp-waste disposal practices were followed. A typhoid fever school-based immunization campaign was safe and logistically possible. Coverage was moderate and can be interpreted as the minimum that could have been achievable because individual written informed consent procedures were sought for the first time in Hue City and the trial nature of the campaign. The lessons learned, together with cost-effectiveness results to be obtained by the end of follow-up period, will hopefully accelerate the introduction of Vi typhoid fever vaccine in Vietnam.
Sujets)
Adolescent , Enfant , Analyse de regroupements , Études de faisabilité , Femelle , Humains , Programmes de vaccination/organisation et administration , Mâle , Vaccination de masse , Polyosides bactériens/effets indésirables , Services de santé scolaire/organisation et administration , Méthode en simple aveugle , Fièvre typhoïde/prévention et contrôle , Vaccins antityphoparatyphoïdiques/effets indésirables , VietnamSujets)
Vaccins antityphoparatyphoïdiques/usage thérapeutique , Vaccination/méthodes , Infections à pneumocoques/prévention et contrôle , Méningite à méningocoques/prévention et contrôle , Vaccins antirabiques , Vaccins antirabiques/effets indésirables , Vaccins antirabiques , Streptococcus pneumoniae/pathogénicité , Vaccins antityphoparatyphoïdiques , Vaccins antityphoparatyphoïdiques/effets indésirablesRésumé
The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.